Study on Immunotherapy for Metastatic Renal Carcinoma
Author Information
Author(s): T. Philip, S. Negrier, C. Lasset, B. Coronel, M. Bret, J.Y. Blay, Y. Merrouche, C. Carrie, P. Kaemmerlen, F. Chauvin, M. Favrot, R. Oskam, I. Tabah, M. Clavel, J.F. Moskovtchenko, A. Mercatello
Primary Institution: Centre Leon Berard
Hypothesis
What are the characteristics and survival rates of patients with metastatic renal carcinoma undergoing immunotherapy with Interleukin 2?
Conclusion
Patients treated with immunotherapy have a median survival of 18 months, significantly better than those not treated.
Supporting Evidence
- Patients treated with cytokines had a median survival of 18 months after metastases.
- The control group had a median survival of 8 months.
- Significant differences in survival were observed between treated and excluded patients.
Takeaway
This study shows that patients who get special cancer treatment tend to live longer, but it also highlights that not everyone can get this treatment.
Methodology
The study analyzed characteristics and survival of 181 patients, comparing those treated with Interleukin 2 to a control group.
Potential Biases
Selection bias due to exclusion of patients with poor prognosis from immunotherapy trials.
Limitations
The study could not perform multivariate analysis due to missing data on important prognostic factors.
Participant Demographics
Patients included were predominantly male, with a median age of 58 years.
Statistical Information
P-Value
<10-6
Statistical Significance
p<10-6
Want to read the original?
Access the complete publication on the publisher's website